Xandra García‐González

Variants in<i>CDA</i>and<i>ABCB1</i>are predictors of capecitabine-related adverse reactions in colorectal cancer

Xandra García‐González, Lucía Cortejoso, María I. García et al. · Oncotarget · 2015 · 64 citations · Full text

Identification of new SNPs associated with severe toxicity to capecitabine

Marta Pellicer, Xandra García‐González, María I. García et al. · Pharmacological Research · 2017 · 48 citations

Medicine, Pharmacology, Pathology +6

Current use of daptomycin and systematic therapeutic drug monitoring: Clinical experience in a tertiary care institution

Alicia Galar, Patricia Muñóz, Maricela Valerio et al. · International Journal of Antimicrobial Agents · 2018 · 47 citations

Therapeutic Drug Monitoring, Medicine, Clinical Pharmacy +7

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

Pilar García‐Alfonso, Miriam Saiz‐Rodríguez, R. Mondéjar et al. · Clinical & Translational Oncology · 2021 · 45 citations · Full text

Cost–Effectiveness of Screening for <i>DPYD</i> Polymorphisms to Prevent Neutropenia in Cancer Patients Treated with Fluoropyrimidines

Lucía Cortejoso, Xandra García‐González, María I. García et al. · Pharmacogenomics · 2016 · 37 citations